Avion Wealth’s Atossa Therapeutics ATOS Stock Holding History

Avion Wealth’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-318	Closed	-$1K	–	1426
2026 Q1	$1K	Buy	+318	New	+$2.01K	﹤0.01%	967

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avion Wealth's ATOS Position: Q2 2026 in Review

Avion Wealth sold out of Atossa Therapeutics (ATOS) in Q2 2026, closing a stake of 318 shares — an estimated $1K sold.

Avion Wealth first reported a position in ATOS in Q1 2026 and held it in 1 quarter. The position peaked at $1K in Q1 2026. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

Avion Wealth reported no remaining Atossa Therapeutics position as of Q2 2026 after selling out during the quarter.
Avion Wealth sold 318 Atossa Therapeutics shares in Q2 2026, an estimated $1K.
Avion Wealth first reported a position in Atossa Therapeutics in Q1 2026 and held it in 1 quarter.
Avion Wealth's Atossa Therapeutics position peaked at $1K in Q1 2026.
31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.